BioNTech
BioNTech SE is a German biotechnology company pioneering messenger RNA (mRNA) therapeutics and individualized cancer immunotherapies. The company structures its operational focus on mRNA drug platforms, cell therapies, and antibody-drug conjugates. Its commercial flagship product is the COVID-19 vaccine Comirnaty (developed with Pfizer), supported by an active clinical oncology pipeline. Primary revenue drivers are commercial vaccine sales, royalty sharing streams, and biopharmaceutical collaboration milestone payments. BioNTech holds a market-leading global position in mRNA-based vaccine development and therapeutic biotechnology. The company is headquartered in Mainz, Germany, and its American Depositary Shares (ADSs) trade on the Nasdaq Global Select Market.
14 of the funds FundTelligence covers report a position in BioNTech.
- Legal name
- BioNTech SE
- Sector
- Health Care
- Country
- Germany
- Funds holding it
- 14
- Exposure themes
- Genetic Medicine, Precision Medicine & Genomics, RNA Therapeutics
Funds holding BioNTech
- Franklin Sustainable Global Growth Fund — Franklin Templeton · 1.56 % (full portfolio disclosed, September 2026)
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 1.25 % (full portfolio disclosed, September 2026)
- SEB Läkemedelsfond — SEB · 1.11 % (full portfolio disclosed, June 2026)
- Handelsbanken Europa — Handelsbanken · 0.69 % (full portfolio disclosed, October 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.66 % (full portfolio disclosed, October 2026)
- SEB Europafond — SEB · 0.58 % (full portfolio disclosed, June 2026)
- SEB European Defence & Security Fund — SEB · 0.49 % (full portfolio disclosed, June 2026)
- Handelsbanken Helse Tema — Handelsbanken · 0.35 % (full portfolio disclosed, October 2026)
Showing the 8 largest of 14 funds holding it.